These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32669577)

  • 61. The effect of TLR9 agonist CpG oligodeoxynucleotides on the intestinal immune response of cobia (Rachycentron canadum).
    Byadgi O; Puteri D; Lee JW; Chang TC; Lee YH; Chu CY; Cheng TC
    J Immunol Res; 2014; 2014():273284. PubMed ID: 24991578
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cytosine-phosphate-guanine oligodeoxynucleotides containing GACGTT motifs enhance the immune responses elicited by keyhole limpet hemocyanin antigen in dairy cattle.
    Chu CY; Lee SC; Liu SS; Lin YM; Shen PC; Yu C; Lee KH; Zhao X; Lee JW
    Nucleic Acid Ther; 2011 Oct; 21(5):323-32. PubMed ID: 21916610
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
    Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
    Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
    [TBL] [Abstract][Full Text] [Related]  

  • 65. CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study.
    Otsuka T; Nishida S; Shibahara T; Temizoz B; Hamaguchi M; Shiroyama T; Kimura K; Miyake K; Hirata H; Mizuno Y; Yagita M; Manabe Y; Kuroda E; Takeda Y; Kida H; Ishii KJ; Kumanogoh A
    BMC Cancer; 2022 Jul; 22(1):744. PubMed ID: 35799134
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination.
    Ma R; Du JL; Huang J; Wu CY
    Biochem Biophys Res Commun; 2007 Sep; 361(2):537-42. PubMed ID: 17662694
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.
    Alizadeh D; Zhang L; Brown CE; Farrukh O; Jensen MC; Badie B
    Clin Cancer Res; 2010 Jul; 16(13):3399-408. PubMed ID: 20570924
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity.
    Yu C; An M; Jones E; Liu H
    Pharm Res; 2018 Feb; 35(3):56. PubMed ID: 29423660
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
    Roda JM; Parihar R; Carson WE
    J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
    [TBL] [Abstract][Full Text] [Related]  

  • 70. S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes.
    Nakagawa T; Tanino T; Onishi M; Tofukuji S; Kanazawa T; Ishioka Y; Itoh T; Kugimiya A; Katayama K; Yamamoto T; Nagira M; Ishii KJ
    Front Immunol; 2021; 12():803090. PubMed ID: 35003132
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
    Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
    J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro.
    Rothenfusser S; Hornung V; Ayyoub M; Britsch S; Towarowski A; Krug A; Sarris A; Lubenow N; Speiser D; Endres S; Hartmann G
    Blood; 2004 Mar; 103(6):2162-9. PubMed ID: 14630815
    [TBL] [Abstract][Full Text] [Related]  

  • 73. CpG ODN 2102 promotes antibacterial immune responses and enhances vaccine-induced protection in golden pompano (Trachinotusovatus).
    Chen X; Wu Y; Qiu Y; Li P; Cao Z; Zhou Y; Sun Y
    Fish Shellfish Immunol; 2023 Jun; 137():108783. PubMed ID: 37137380
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The secretion of IL-6 by CpG-ODN-treated cancer cells promotes T-cell immune responses partly through the TLR-9/AP-1 pathway in oral squamous cell carcinoma.
    Ruan M; Thorn K; Liu S; Li S; Yang W; Zhang C; Zhang C
    Int J Oncol; 2014 Jun; 44(6):2103-10. PubMed ID: 24676671
    [TBL] [Abstract][Full Text] [Related]  

  • 75. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).
    Weeratna RD; Makinen SR; McCluskie MJ; Davis HL
    Vaccine; 2005 Nov; 23(45):5263-70. PubMed ID: 16081189
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Toll-like receptor 9 ligand blocks osteoclast differentiation through induction of phosphatase.
    Amcheslavsky A; Bar-Shavit Z
    J Bone Miner Res; 2007 Aug; 22(8):1301-10. PubMed ID: 17488193
    [TBL] [Abstract][Full Text] [Related]  

  • 77. CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications.
    Becker Y
    Virus Genes; 2005 Mar; 30(2):251-66. PubMed ID: 15744581
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells.
    Nierkens S; den Brok MH; Garcia Z; Togher S; Wagenaars J; Wassink M; Boon L; Ruers TJ; Figdor CG; Schoenberger SP; Adema GJ; Janssen EM
    Cancer Res; 2011 Oct; 71(20):6428-37. PubMed ID: 21788345
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Leishmanial CpG DNA nanovesicles: A propitious prophylactic approach against visceral leishmaniasis.
    Tiwari RK; Chandrakar P; Gupta CL; Sayyed U; Shekh R; Bajpai P
    Int Immunopharmacol; 2021 Jan; 90():107181. PubMed ID: 33249044
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients.
    Winckelmann AA; Munk-Petersen LV; Rasmussen TA; Melchjorsen J; Hjelholt TJ; Montefiori D; Østergaard L; Søgaard OS; Tolstrup M
    PLoS One; 2013; 8(4):e62074. PubMed ID: 23637967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.